Discussion
Inmune Bio plans to submit regulatory applications in the U.K., U.S., and European Union seeking approval of Ebstrocel, its experimental stem cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company expects to file its application in the U.K. before the end of this year, followed by…